share_log

Raymond James Maintains Outperform on Leap Therapeutics, Lowers Price Target to $17.5

Benzinga ·  Nov 14, 2023 16:42

Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $18.5 to $17.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment